Mr. Brown, perhaps I may add something to Joyce's comments.
One of the really exciting things that's going on right now that Parkinson Society Canada is starting to fund as well is that within pharmaceutical industries, we know that a Tylenol not only treats headache but can also bring down fever. We know that Aspirin not only can prevent heart disease but also can cure our aching bones. That effort of using one drug for multiple purposes is called drug repositioning.
One of the exciting things that began in the ALS and Huntington's disease arena is to come up with strategies of how can we reposition drugs that are already approved by Health Canada and the FDA and European commissions to apply them to Parkinson's disease. That's something that is going on worldwide now and is pursued by a number of foundations.
Just four days ago, in San Diego, I was approached by the head of neuroscience research from Pfizer, who asked me to help them confirm what drugs they have that could work in Parkinson's disease models.
So this whole notion of drug repositioning could cut down ten years of development of a new drug and could cut the cost from $750 million down to $5 million or less to actually bring a drug to market. Drug repositioning is part of a portfolio of many foundations and national institutions, and that's something that I think Canada could contribute to as well.